A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety of ranolazine in people with pulmonary
arterial hypertension (PAH) and who are receiving 1 or more background PAH therapies:
ambrisentan, sildenafil,tadalafil, epoprostenol, treprostinil (IV, SC, inhaled), or iloprost.
The primary objective is:
- To estimate the effect of ranolazine administration on acute hemodynamics.
- To assess safety of ranolazine acutely over 6 hrs in the catheterization lab and after
12 weeks of therapy
- To assess changes in right ventricular function after 12 weeks of therapy.